Artiva highlights Phase 2a AlloNK plus rituximab data in Sjögren disease showing six-month symptom improvement
ARTV•Artiva highlighted Phase 2a data showing clinically meaningful improvements in disease activity, patient-reported symptoms and salivary function after six months of AlloNK plus rituximab in Sjögren disease.
1. Six-month trial results
Updated Phase 2a data for AlloNK (AB-101) plus rituximab in Sjögren disease were presented at ISSjD 2026, covering patients with at least six months of follow-up as of the July 2, 2026 cutoff. An expanded safety update across 73 Phase 2a patients supported an outpatient approach, with no discontinuations tied to adverse events.
